In 2018, KDIGO issued a clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease.1 Recently, KDOQI published a commentary on the KDIGO guideline in which members of the appointed group disagreed with Recommendation 4.2.2 to direct HCV nucleic acid test (NAT)-positive kidneys to HCV NAT-positive recipients.2 They commented that recent studies demonstrated viral eradication with direct-acting antivirals (DAAs) in HCV NAT-negative patients who received HCV NAT-positive kidneys, thus providing evidence that such kidneys could be allocated to any recipients regardless of their HCV status.